Literature DB >> 6244091

Properties of a calcitonin receptor and adenylate cyclase in BEN cells, a human cancer cell line.

D M Findlay, M deLuise, V P Michelangeli, M Ellison, T J Martin.   

Abstract

A human lung cancer cell line (BEN cells) was found to have a calcitonin-responsive adenylate cyclase. Various calcitonins and synthetic analogs stimulated adenylate cyclase activity withe same relative potency as they show in lowering blood calcium in the rat. Preincubation of the cells with calcitonin, followed by washing, led to loss of subsequent adenylate cyclase response to hormone. This was a dose-dependent phenomenon. The binding of [125I]salmon calcitonin to freshly subcultured cells was studied. The ability of calcitonins and analogs to compete for binding paralleled their efficacies in stimulating adenylate cyclase. Binding was saturable, reversible, and consisted of a single class of noninteracting sites with a mean Kd of 10.75 X 10(-10) M, K of 0.93 X 10(9)/M, and mean receptor number of 2.71 X 10(4)/cell. It is not known whether the calcitonin receptor is inappropriate to the cell of origin of the tumor. The BEN cells provide a means of isolating and studying the properties of the calcitonin receptor and of evaluating the significance for the tumor of a hormone-responsive adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6244091

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization.

Authors:  G C Nicholson; J M Moseley; P M Sexton; F A Mendelsohn; T J Martin
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

Review 2.  Peptides from the calcitonin genes: molecular genetics, structure and function.

Authors:  L H Breimer; I MacIntyre; M Zaidi
Journal:  Biochem J       Date:  1988-10-15       Impact factor: 3.857

Review 3.  Central nervous system binding sites for calcitonin and calcitonin gene-related peptide.

Authors:  P M Sexton
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

4.  Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin.

Authors:  S M Forrest; K W Ng; D M Findlay; V P Michelangeli; S A Livesey; N C Partridge; J D Zajac; T J Martin
Journal:  Calcif Tissue Int       Date:  1985-01       Impact factor: 4.333

5.  Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary.

Authors:  J A Fischer; P H Tobler; M Kaufmann; W Born; H Henke; P E Cooper; S M Sagar; J B Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

6.  Gene organization and alternative splicing of human prohormone convertase PC8.

Authors:  K A Goodge; R J Thomas; T J Martin; M T Gillespie
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

7.  Reversible calcitonin binding to solubilized sheep brain binding sites.

Authors:  P M Sexton; H G Schneider; C S D'Santos; F A Mendelsohn; B E Kemp; J M Moseley; T J Martin; D M Findlay
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

8.  Effect of human calcitonin (hCT) on glucose- and arginine-stimulated insulin secretion.

Authors:  S Sgambato; N Passariello; G Paolisso; A Marano; R Buoninconti; P Tesauro
Journal:  Acta Diabetol Lat       Date:  1986 Jan-Mar

9.  Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line.

Authors:  A H Gorn; H Y Lin; M Yamin; P E Auron; M R Flannery; D R Tapp; C A Manning; H F Lodish; S M Krane; S R Goldring
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  Parathyroid hormone-related protein purified from a human lung cancer cell line.

Authors:  J M Moseley; M Kubota; H Diefenbach-Jagger; R E Wettenhall; B E Kemp; L J Suva; C P Rodda; P R Ebeling; P J Hudson; J D Zajac
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.